Novartis Pharmaceuticals Canada Inc.
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
CC on an email message to department staff regarding Health Canada Approval of an important new therapy.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
|
|
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical, Laboratory & Blood Services Division (PLBSD) will be making future funding decisions.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health, Hospitals, Senior Citizens
|
|
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health, Hospitals
|
|
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative pharmaceutical treatments for BC citizens that require publicly funded access to these treatments, through various BC government programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Hospitals, Science and Technology, Senior Citizens
|
|
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Hospitals
|
|
Meeting request to explore and understand BC Ministry of Health challenges, barriers, timelines and possible solutions to enable patients to be treated with innovative specialized therapies at sites in BC. (BC patients currently do not have access or are traveling to out-of-province jurisdictions to receive some innovative therapies.)
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Meetings with government officials regarding government funding to facilitate patient access to Novartis pharmaceutical treatments
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
|
|
Meeting with the Minister of Jobs, Economic Development and Innovation to discuss the BC Life Sciences Strategy and Novartis' role as a key partner in the province's bioscience ecosystem, including data partnerships, patient access to innovative medicines and expanded access to diagnostic equipment.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Science and Technology
|
|
Request a meeting to discuss innovative program pioneered by the NHS (England) to address cardiovascular disease risk factor mitigation through a collaborative program created to identify and treat patients high risk for CVD due to elevated cholesterol levels that does not meet current Clinical Guideline standards as published by the Canadian Cardiovascular Congress. Enacting such a program in BC will impact health system resource use caused by the downstream impact of Cardiovascular disease; heart attack, stroke, etc.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health, Hospitals, Senior Citizens
|